Roswell Park immunologists identify targetable strategy for reducing solid-tumor cancer metastasis

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A team of scientists led by Scott Abrams at Roswell Park Comprehensive Cancer Center uncovered a pathway associated with metastases to the lung, a common site for cancer spread. The work, just published in JCI Insight, has potentially significant implications that may point to novel cancer therapies.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Divarasib, a next-generation KRAS G12C inhibitor, lowered the risk of disease progression or death by 42% and the overall risk of death by 44% in people with previously treated KRAS G12C-mutated non-small cell lung cancer, according to the results from the phase III Krascendo 1 study. The therapy demonstrated the superior efficacy compared with current standard of care KRAS G12C inhibitors. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login